PCOS Renamed as PMOS in Landmark Move to Improve Global Diagnosis and Women’s Healthcare

In a major step toward better awareness and treatment, the condition long known as Polycystic Ovary Syndrome (PCOS) has officially been renamed Polyendocrine Metabolic Ovarian Syndrome (PMOS). The disorder affects more than 170 million women globally, or roughly 1 in 8 women, and experts say the new name more accurately reflects its complex nature.

The renaming initiative was the result of a 14-year international collaboration involving over 50 medical and patient advocacy organizations, including the Endocrine Society. The announcement and findings were published in The Lancet.

Health experts explained that the old term “PCOS” often created confusion by focusing on ovarian cysts, despite evidence showing that abnormal cysts are not a defining feature of the condition. This misunderstanding frequently led to delayed diagnoses, incomplete treatment, and a narrow view of a disorder that also impacts hormones, metabolism, mental health, skin, weight management, and reproductive health.

Professor Helena Teede of Monash University, who led the global process, said the new terminology is designed to improve recognition and long-term care for millions of women. She noted that although medical guidelines have improved over time, changing the name was essential to better reflect the science and lived experiences of patients.

The consultation process included more than 22,000 survey responses, workshops with healthcare professionals, and direct input from women living with the condition across multiple countries.

Experts also emphasized the importance of selecting a name that works across cultures and avoids unnecessary stigma, especially in regions where reproductive terminology can carry social sensitivity.

A three-year transition period has now begun, with global education campaigns underway. PMOS is expected to be fully adopted in the 2028 International Guideline update.

Patient advocates welcomed the change, calling it a historic moment that could lead to earlier diagnosis, fairer healthcare access, and stronger research investment for future generations.

Source: Endocrine Society